Literature DB >> 8443039

Interactions among primaquine, malaria infection and other antimalarials in Thai subjects.

G Edwards1, C S McGrath, S A Ward, W Supanaranond, S Pukrittayakamee, T M Davis, N J White.   

Abstract

1. The pharmacokinetics of rac-primaquine (45 mg base) and its principal plasma metabolite, carboxyprimaquine have been investigated in healthy Thai adults prior to and following a single oral dose of mefloquine (10 mg kg-1). 2. Primaquine was rapidly absorbed, attaining peak plasma concentrations (median and range) of 167 (113-532) micrograms l-1 in 2 (1-4) h. Thereafter, concentrations declined rapidly with an apparent terminal half-life of 6.1 (1.7-16.1) h and an oral clearance (CLpo) of 33.1 (17.6-49.3) l h-1. Administration of mefloquine had no effect on the values of any of these parameters at the 5% level of significance [Cmax 229 (114-503) micrograms l-1; tmax 3 (2-4) h; t1/2,z 3.9 (1.7-13.5) h; CLpo 34.0 (21.7-49.0) l h-1]. 3. The carboxylic acid metabolite of primaquine achieved maximum concentrations (median and range) of 890 (553-3634) micrograms l-1 at 6 (3-16) h. Thereafter, plasma concentrations of carboxyprimaquine declined to 346 (99-918) micrograms l-1 at 24 h. AUC (0,24 h) was 12737 (6837-27388) micrograms l-1 h. Administration of mefloquine had no effect on the plasma concentrations of this metabolite [Cmax 1035 (174-3015) micrograms l-1; tmax 8 (2-24) h; AUC(0,24) 13471 (2132-17863) micrograms l-1 h]. 4. The effect of falciparum malaria and treatment with quinine (10 mg salt kg-1 p.o.) on the pharmacokinetics of primaquine (45 mg base p.o.) has been investigated in adult Thai patients during and after infection with falciparum malaria.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8443039      PMCID: PMC1381514          DOI: 10.1111/j.1365-2125.1993.tb05685.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  The effects of primaquine stereoisomers and metabolites on drug metabolism in the isolated perfused rat liver and in vitro rat liver microsomes.

Authors:  G W Mihaly; S A Ward; D D Nicholl; G Edwards; A M Breckenridge
Journal:  Biochem Pharmacol       Date:  1985-02-01       Impact factor: 5.858

2.  Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects.

Authors:  S A Ward; G W Mihaly; G Edwards; S Looareesuwan; R E Phillips; P Chanthavanich; D A Warrell; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

3.  Metabolism of 8-aminoquinoline antimalarial agents.

Authors:  A Strother; I M Fraser; R Allahyari; B E Tilton
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

4.  In vitro metabolism of the antimalarial agent primaquine by mouse liver enzymes and identification of a methemoglobin-forming metabolite.

Authors:  A Strother; R Allahyari; J Buchholz; I M Fraser; B E Tilton
Journal:  Drug Metab Dispos       Date:  1984 Jan-Feb       Impact factor: 3.922

5.  Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite.

Authors:  G W Mihaly; S A Ward; G Edwards; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

6.  In vitro effects of quinoline derivatives on cytochrome P-450 and aminopyrine N-demethylase activity in rat hepatic microsomes.

Authors:  M Murray
Journal:  Biochem Pharmacol       Date:  1984-10-15       Impact factor: 5.858

7.  Effect of mefloquine on hepatic drug metabolism in the rat: comparative study with primaquine.

Authors:  J H Riviere; D J Back
Journal:  Biochem Pharmacol       Date:  1985-02-15       Impact factor: 5.858

8.  Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs.

Authors:  K N Bangchang; J Karbwang; D J Back
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

9.  Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size.

Authors:  G W Mihaly; S A Ward; G Edwards; D D Nicholl; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

10.  Impairment of hepatic cytochrome P-450-dependent monooxygenases by the malaria parasite Plasmodium berghei.

Authors:  A P Alvares; T H Ueng; L W Scheibel; M R Hollingdale
Journal:  Mol Biochem Parasitol       Date:  1984-11       Impact factor: 1.759

View more
  16 in total

Review 1.  Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations.

Authors:  Hla Y Myint; Jonathan Berman; Larry Walker; Brandon Pybus; Victor Melendez; J Kevin Baird; Colin Ohrt
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

Review 2.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Absence of significant pharmacokinetic and pharmacodynamic interactions between artemether and quinoline antimalarials.

Authors:  K Na-Bangchang; J Karbwang; R Ubalee; A Thanavibul; S Saenglertsilapachai
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

4.  Paracetamol disposition in Thai patients during and after treatment of falciparum malaria.

Authors:  S Ismail; K Na Bangchang; J Karbwang; D J Back; G Edwards
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.

Authors:  Brioni R Moore; Sam Salman; John Benjamin; Madhu Page-Sharp; Leanne J Robinson; Elizabeth Waita; Kevin T Batty; Peter Siba; Ivo Mueller; Timothy M E Davis; Inoni Betuela
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

Review 6.  Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common.

Authors:  Nicholas J White; Li Guo Qiao; Gao Qi; Lucio Luzzatto
Journal:  Malar J       Date:  2012-12-14       Impact factor: 2.979

7.  Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination.

Authors:  Jaline Gerardin; Philip Eckhoff; Edward A Wenger
Journal:  BMC Infect Dis       Date:  2015-03-22       Impact factor: 3.090

8.  Pharmacokinetic interactions between primaquine and chloroquine.

Authors:  Sasithon Pukrittayakamee; Joel Tarning; Podjanee Jittamala; Prakaykaew Charunwatthana; Saranath Lawpoolsri; Sue J Lee; Warunee Hanpithakpong; Borimas Hanboonkunupakarn; Nicholas P J Day; Elizabeth A Ashley; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

9.  Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects.

Authors:  Podjanee Jittamala; Sasithon Pukrittayakamee; Elizabeth A Ashley; François Nosten; Borimas Hanboonkunupakarn; Sue J Lee; Praiya Thana; Kalayanee Chairat; Daniel Blessborn; Salwaluk Panapipat; Nicholas J White; Nicholas P J Day; Joel Tarning
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

10.  Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects.

Authors:  Borimas Hanboonkunupakarn; Elizabeth A Ashley; Podjanee Jittamala; Joel Tarning; Sasithon Pukrittayakamee; Warunee Hanpithakpong; Palang Chotsiri; Thanaporn Wattanakul; Salwaluk Panapipat; Sue J Lee; Nicholas P J Day; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.